Lupin concludes USFDA inspection at Aurangabad facility with one observation

31 Jul 2017 Evaluate

Lupin has successfully completed a PAI inspection (Prior Approval Inspection) carried out by the United States Food and Drug Administration (USFDA) at its Aurangabad manufacturing facility with one 483 observation. The observation was procedural in nature and corrected during the inspection itself.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2321.00 -13.95 (-0.60%)
30-Mar-2026 12:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.40
Dr. Reddys Lab 1264.20
Cipla 1230.15
Zydus Lifesciences 887.70
Lupin 2321.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×